• Earlier in June 2026, Expensify, Inc. completed a self-tender offer that expired on June 10, with 6,140,642 Class A shares validly tendered at US$1.20 per share.
• Around the same time, Expensify launched its Expensify MCP integration, allowing popular AI assistants like ChatGPT and Claude to securely query users’ expense data in real time without manual exports.
• We’ll now examine how this new AI-powered MCP integration could reshape Expensify’s previously outlined investment narrative and future business profile.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Expensify Investment Narrative Recap

To own Expensify today, you need to believe its expense and spend-management “superapp” can eventually scale to profitability despite ongoing losses and intense AI-driven competition. The recent self-tender at US$1.20 per share looks more like capital-structure housekeeping than a change to the core story, while the key near-term catalyst and risk still center on whether rising product sophistication can convert awareness into paying, sticky SMB customers before cash burn and margin pressure become harder to ignore.

The new Expensify MCP integration is especially relevant here, because it puts Expensify’s AI ambitions directly in front of users through tools like ChatGPT and Claude. If this natural language access to real-time expense data improves workflows and perceived value, it could support the thesis that deeper AI integration is a meaningful differentiator rather than a commodity feature, giving the company a clearer path to converting its product-led model into higher paid adoption and more resilient revenue.

Yet beneath the product progress, investors should be aware that rising AI competition and persistent losses could still pressure Expensify’s options...

Expensify's narrative projects $131.0 million revenue and $15.8 million earnings by 2029.

Uncover how Expensify's forecasts yield a $1.12 fair value, a 28% downside to its current price.

Exploring Other Perspectives

Compared with consensus, the most pessimistic analysts saw revenue slipping to about US$129.9 million and still unprofitable by 2029, so even news like MCP and the buyback may or may not shift that more cautious view on AI commoditization and SMB churn, and you should weigh how far your own expectations sit between these very different outlooks.

Explore 4 other fair value estimates on Expensify - why the stock might be worth as much as 56% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Expensify research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Expensify research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Expensify's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.